Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remifentanil effect-site concentration plus TEAS to reduce propofol use during thoracoscopic lobectomy
ChiCTR1800014987Phase 4Recruiting
- Sponsor
- Beijing Hospital
- Start
- Mar 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remifentanil and propofol in lung neoplasm (4 arms), sponsored by Beijing Hospital. Primary endpoints: Propofol dosage and Global score. Started Mar 2018; status: recruiting.
02
Drugs
remifentanilpropofol
03
Conditions
lung neoplasm
Beyond the preview
Go deeper on ChiCTR1800014987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014987.